WHO global research priorities for antimicrobial resistance in human health
The WHO research agenda for antimicrobial resistance (AMR) in human health has
identified 40 research priorities to be addressed by the year 2030. These priorities focus on …
identified 40 research priorities to be addressed by the year 2030. These priorities focus on …
A scoping review describes methods used to identify, prioritize and display gaps in health research
L Nyanchoka, C Tudur-Smith, V Iversen… - Journal of clinical …, 2019 - Elsevier
Abstract Background and Objectives Different methods to examine research gaps have
been described, but there are still no standard methods for identifying, prioritizing, or …
been described, but there are still no standard methods for identifying, prioritizing, or …
Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out
Despite wide antiretroviral scale-up during the past two decades resulting in declining new
infections and mortality globally, HIV-associated tuberculosis remains as a major public …
infections and mortality globally, HIV-associated tuberculosis remains as a major public …
[HTML][HTML] Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases
Prevention of multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB)
is a top priority for global TB control, given the need to limit epidemic spread and …
is a top priority for global TB control, given the need to limit epidemic spread and …
Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis
Objectives: To estimate the prevalence of adverse drug reactions or events (ADR) during
drug-resistant TB (DR-TB) treatment in the context of settings with high HIV prevalence (at …
drug-resistant TB (DR-TB) treatment in the context of settings with high HIV prevalence (at …
[HTML][HTML] Global knowledge gaps on antimicrobial resistance in the human health sector: A scoping review
Objectives To identify and summarize existing global knowledge gaps on antimicrobial
resistance (AMR) in human health, focusing on the World Health Organization (WHO) …
resistance (AMR) in human health, focusing on the World Health Organization (WHO) …
[HTML][HTML] Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis
L Fu, T Weng, F Sun, P Zhang, H Li, Y Li, Q Yang… - International Journal of …, 2021 - Elsevier
Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda-a case-control study
E Kizito, J Musaazi, K Mutesasira… - BMC infectious …, 2021 - Springer
Abstract Background The World Health Organization (WHO) End TB strategy aims to reduce
mortality due to tuberculosis (TB) to less than 5% by 2035. However, mortality due to …
mortality due to tuberculosis (TB) to less than 5% by 2035. However, mortality due to …
Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study
C Perrin, K Athersuch, G Elder, M Martin… - BMJ Global …, 2022 - gh.bmj.com
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the
nitroimidazole delamanid—as well as pretomanid from the same class of drugs as …
nitroimidazole delamanid—as well as pretomanid from the same class of drugs as …
Latent tuberculous infection in household contacts of multidrug-resistant and newly diagnosed tuberculosis
BACKGROUND: Differences in the prevalence of latent tuberculous infection (LTBI) and
tuberculosis (TB) disease among contacts of patients with multidrug-resistant TB (MDR-TB) …
tuberculosis (TB) disease among contacts of patients with multidrug-resistant TB (MDR-TB) …